2016

Brazzelli, M, Hawkins, N, McKeekin, N, Goulao, B, Cooper, D, Sharma, P, Fraser, C, Nicolson, M,Wu, O. Pembrolizumab after platinum chemotherapy for treating advanced, recurrent, PD-L1 positive, non-small cell lung cancer. . Evidence Review Group report in support of the NICE STA University of Aberdeen: Health Services Research Unit; 2016

Cummins, E, Culligan, D, Cooper, D, Fraser, C, Robertson, C,Ramsay, C, R. Ibrutinib for treating relapsed or refractory chronic lymphocytic leukaemia Evidence Review Group report in support of the NICE STA Programme. University of Aberdeen: Health Services Research Unit; 2016

Cummins, E, Ayansina, D, Sharma, P, Fraser, C, Shimonovich, M, McLean, M,Brazzelli, M. Eluxadoline for treating irritable bowel syndrome with diarrhoea. Evidence Review Group report in support of NICE STA programme. University of Aberdeen: Health Services Research Unit; 2016

Scotland, G, Hernandez, R, Robertson, C, Scott, N,Fraser, C. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (men who have not received docetaxel and for whom docetaxel is contraindicated or not suitable).  ERG critique of the company submission for re-consideration of current CDF technologies under the new proposed CDF criteria. University of Aberdeen: Health Services Research Unit; 2016

Scott, N, Cummins, E, Cruickshank, M, Fraser, C, Lois, N,Brazzelli, M. Aflibercept for treating visual impairment due to macular oedema secondary to branch vein occlusion: a single technology appraisal. . Evidence Review Group report in support of the NICE STA Programme. . University of Aberdeen: Health Services Research Unit; 2016